Terms: = Endocrine gland cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Diagnosis
9 results:
1. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
2. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Rev Esp Patol; 2023; 56(1):32-44. PubMed ID: 36599598
[TBL] [Abstract] [Full Text] [Related]
3. Exceptional Response to Erdafitinib in fgfr2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract] [Full Text] [Related]
4. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de-Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Clin Transl Oncol; 2022 Nov; 24(11):2107-2119. PubMed ID: 36008616
[TBL] [Abstract] [Full Text] [Related]
5. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract] [Full Text] [Related]
6. The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract] [Full Text] [Related]
7. [Quality of life in patients with pituitary adenomas in the pre- and postoperative period].
Cherebillo VY; Kurnukhina MY
Zh Vopr Neirokhir Im N N Burdenko; 2019; 83(2):11-16. PubMed ID: 31166313
[TBL] [Abstract] [Full Text] [Related]
8. MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting fgfr2.
Fu YT; Zheng HB; Zhang DQ; Zhou L; Sun H
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3430-3438. PubMed ID: 29917195
[TBL] [Abstract] [Full Text] [Related]
9. Fibroblast growth factor receptor-2 expression in thyroid tumor progression: potential diagnostic application.
Redler A; Di Rocco G; Giannotti D; Frezzotti F; Bernieri MG; Ceccarelli S; D'Amici S; Vescarelli E; Mitterhofer AP; Angeloni A; Marchese C
PLoS One; 2013; 8(8):e72224. PubMed ID: 23977259
[TBL] [Abstract] [Full Text] [Related]
